Literature DB >> 19727253

Choosing Antidepressants for HIV and AIDS Patients: Insights on Safety and Side Effects.

Jason Yanofski1, Paul Croarkin.   

Abstract

Human immunodeficiency virus (HIV) has a high comorbidity with major depression. Symptoms of depression may be attributed to ongoing HIV infection, thereby reducing the likelihood of timely treatment with antidepressants. This may contribute to the morbidity of both illnesses. This review focuses on an evidence-based approach to selecting antidepressants for first-line treatment of major depressive disorder in patients with HIV and acquired immune deficiency syndrome (AIDS). Some antidepressant medications have side effect profiles that may exacerbate the symptoms commonly seen in patients with HIV and AIDS. Others have side effects that, while normally problematic in the general population, may be helpful in counteracting the difficulties seen in HIV and AIDS patients. Other challenges in treatment include an array of possible drug-drug interactions between antidepressants and HIV medications. Clinicians should focus more on capitalizing on the side effects of psychotropic medications in this patient population than on trying to avoid drug-drug interactions.

Entities:  

Keywords:  AIDS; HIV; antidepressants; major depressive disorder

Year:  2008        PMID: 19727253      PMCID: PMC2686642     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  22 in total

1.  Mirtazapine for depression in patients with human immunodeficiency virus.

Authors:  A J Elliott; P P Roy-Byrne
Journal:  J Clin Psychopharmacol       Date:  2000-04       Impact factor: 3.153

2.  Psychological and physical health correlates of body cell mass depletion among HIV+ men.

Authors:  G J Wagner; S J Ferrando; J G Rabkin
Journal:  J Psychosom Res       Date:  2000-07       Impact factor: 3.006

3.  Seizures after buproprion overdose.

Authors:  I Mainie; C McGurk; G McClintock; J Robinson
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

Review 4.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 5.  Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.

Authors:  Henricus G Ruhé; Jochanan Huyser; Jan A Swinkels; Aart H Schene
Journal:  J Clin Psychiatry       Date:  2006-12       Impact factor: 4.384

Review 6.  [The effectiveness of antidepressants in the treatment of chronic non-cancer pain--a review].

Authors:  Adam Miller; Jolanta Rabe-Jabłońska
Journal:  Psychiatr Pol       Date:  2005 Jan-Feb       Impact factor: 1.657

Review 7.  Antidepressant treatment of the depressed patient with insomnia.

Authors:  M E Thase
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

8.  Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.

Authors:  Rob E Aarnoutse; Johanneke Kleinnijenhuis; Peter P Koopmans; Daan J Touw; Jaap Wieling; Yechiel A Hekster; David M Burger
Journal:  Clin Pharmacol Ther       Date:  2005-12       Impact factor: 6.875

Review 9.  Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV.

Authors:  Joshua Caballero; Milap C Nahata
Journal:  Ann Pharmacother       Date:  2004-11-23       Impact factor: 3.154

10.  The STAR*D Project results: a comprehensive review of findings.

Authors:  Diane Warden; A John Rush; Madhukar H Trivedi; Maurizio Fava; Stephen R Wisniewski
Journal:  Curr Psychiatry Rep       Date:  2007-12       Impact factor: 5.285

View more
  6 in total

Review 1.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

2.  Comparative effectiveness of dual vs. single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression.

Authors:  Jon C Mills; Jeffrey S Harman; Robert L Cook; Nicole M Marlow; Christopher A Harle; R Paul Duncan; Bradley N Gaynes; Brian W Pence
Journal:  AIDS       Date:  2017-11-28       Impact factor: 4.177

Review 3.  Group psychotherapies for depression in persons with HIV: A systematic review.

Authors:  Abhijit Ramanna Honagodu; Murali Krishna; Rajesh Sundarachar; Peter Lepping
Journal:  Indian J Psychiatry       Date:  2013-10       Impact factor: 1.759

4.  The impact of HIV/AIDS on compliance with antidepressant treatment in major depressive disorder: A prospective study in a South African private healthcare cohort.

Authors:  Francois N Slabbert; Brian H Harvey; Christiaan B Brink; Martie S Lubbe
Journal:  AIDS Res Ther       Date:  2015-04-14       Impact factor: 2.250

5.  INtegration of DEPression Treatment into HIV Care in Uganda (INDEPTH-Uganda): study protocol for a randomized controlled trial.

Authors:  Glenn J Wagner; Victoria Ngo; Peter Glick; Ekwaro A Obuku; Seggane Musisi; Dickens Akena
Journal:  Trials       Date:  2014-06-25       Impact factor: 2.279

6.  HIV, multidrug-resistant TB and depressive symptoms: when three conditions collide.

Authors:  Mrinalini Das; Petros Isaakidis; Rafael Van den Bergh; Ajay M V Kumar; Sharath Burugina Nagaraja; Asmaa Valikayath; Santosh Jha; Bindoo Jadhav; Joanna Ladomirska
Journal:  Glob Health Action       Date:  2014-09-09       Impact factor: 2.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.